Importance of 6-Thioguanine Nucleotide Metabolite Monitoring in Inflammatory Bowel Disease Patients Treated with Azathioprine

1. Sandborn W, Sutherland L, Pearson D, et al. Azathioprine or 6-mercaptopurine for induction of remission of Crohn’s disease. Cohrane Database System Rev.2, CDOOO545.Search in Google Scholar

2. Smith M, Blacker P, Patel C, et al. The impact of introducing thioguanine nucleotide monitoring into an inflammatory bowel disease clinic. Int J Clin Pract. 2013; 67(2): 161-9.10.1111/ijcp.12039Search in Google Scholar

3. Connell WR, Kamm MA, Ritchie JK, et al. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993; 34: 1081-5.10.1136/gut.34.8.1081Search in Google Scholar

4. D’Halluin PN, Tribut O, Branger B, et al. RBC 6-TGN and hematological parameters in patients with Crohn’s disease treated by azathioprine. Gastroenterol Clin Biol. 2005; 29: 1264-9.1651828510.1016/S0399-8320(05)82219-5Search in Google Scholar

5. Cuffari C, Hunt S, Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimize azathioprine therapy in patients with inflammatory bowel disease. Gut. 2011; 48: 642-6.10.1136/gut.48.5.642172827811302961Search in Google Scholar

6. Declaration of Helsinki, Ethical Principles for Medical Research Involving Human Subject as amended. Helsinki. 2013.Search in Google Scholar

7. Al Hadithy AF, de Boer NK, Derijks LJ, et al. Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations. Dig Liver Dis. 2005; 37: 282-97.10.1016/j.dld.2004.09.02915788214Search in Google Scholar

8. Saibeni S, Virgilio T, D’Inca R, et al. The use of thiopurines for the treatment of inflammatory bowel diseases in clinical practice. Dig Liver Dis. 2008; 40(10): 814–20.10.1016/j.dld.2008.03.01618479986Search in Google Scholar

9. McLean L, Cross R. Adverse events in IBD: to stop or continue immune suppressant and biologic treatment. Expert Rev Gastroenterol Hepatol. 2014; 8(3): 223-40.10.1586/17474124.2014.881715414008624490595Search in Google Scholar

10. Chaparro M, Ordas I, Cabre E, et al. Safety of thiopurine therapy in inflammatory bowel disease: long-term follow up study of 3931 patients. Inflamm Bowel Dis.2013; 19(7): 1404-10.10.1097/MIB.0b013e318281f28f23665964Search in Google Scholar

11. Ansari A, Hassan C, Duley J, et al. Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther. 2002; 16: 1743-50.10.1046/j.1365-2036.2002.01353.x12269967Search in Google Scholar

12. Hindorf U, Lindqvist M, Peterson C, et al. Pharmacogenetics during standardised iniciation of thiopurine treatment in inflammatory bowel disease. Gut. 2006; 55: 1423-31.10.1136/gut.2005.074930185643616543290Search in Google Scholar

13. Lee MN, Kang B, Choi SY, et al. Relationship between azathioprine dosage, 6-thioguanine nucleotide levels, and therapeutic response in pediatric patients with IBD treated with azathioprine. Inflamm Bowel Dis. 2015; 21(5): 1054-62.10.1097/MIB.0000000000000347Search in Google Scholar

14. Zhang B, Xu X, Zeng X, et al. Correlation of Thiopurine Methyltransferase Activity and 6- Thioguanine Nucleotide Concentration in Han Chinese Patients treated with Azathioprine 25 to 100mg: A 1-Year Single-Center, Prospective study. Cur Ther Research. 2006; 67(4): 270-82.10.1016/j.curtheres.2006.07.002Search in Google Scholar

15. Gearry RB, Barclay ML, Roberts RL, et al. Thiopurine methyltransferase and 6-thioguanine nucleotide measurement: early experience of use in clinical practice. Inter Med J. 2005; 35(10): 580-5.10.1111/j.1445-5994.2005.00904.xSearch in Google Scholar

16. Cohen R. Forecast for using metabolite measurements in the dosing of azathioprine or 6-mercaptopurine for IBD patients: “Partly cloudy”. Gastroenterol 2002; 122: 2082-84.10.1016/S0016-5085(02)70022-XSearch in Google Scholar

17. Lowry PW, Franklin CL, Weaver AL, et al. Leukopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut. 2001; 49: 656-64.10.1136/gut.49.5.656172849011600468Search in Google Scholar

18. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease; a 30 year review. Gut. 2002; 50: 485-9.10.1136/gut.50.4.485177316211889067Open DOISearch in Google Scholar